Felbamate

Epilepsy is one of the most common neurologic disorders, affecting about 1% of the U.S. population. More than 30% of patients with epilepsy experience either adverse effects or inadequate seizure control with traditional antiepileptic medications. Felbamate (Felbatol) is a new antiepileptic drug whose mechanism of action remains unknown. It has more complicated pharmacokinetics and more drug interactions than the other new antiepileptic drugs. Because of potentially fatal adverse effects of aplastic anemia and hepatic failure, Felbamate's use is restricted to patients with severe epilepsy refractory to other therapies.

Daily doses in the range of 1200 to 3600 mg per day normally produce serum concentrations of 25 to 100 ug/mL. Levels of 200 ug/mL or higher are considered critical.

Specimen requirement is one plain red top tube of blood drawn one hour prior to the next dose.




Factor V Leiden Factor VIII & Thrombosis Factor VIII Inhibitor Factor X Chromogenic Assay Factor Xa Inhibitors Factor XI Level Associated with Stroke Factor XII Factor XIII Fecal Fat Qualitative Fecal Fat Quantitative Fecal Leukocytes Fecal Occult Blood Test Felbamate Ferritin Fetal Fibronectin Fetal Lung Maturity Profile Fibrin Degradation Products Fibrinogen FK506 Flow Cytometry Indications Folate Follicle Stimulating Hormone Fosphenytoin Fourteen Three Three Protein Fungal Blood Cultures